Acta Med. 2014, 57: 56-61

https://doi.org/10.14712/18059694.2014.40

THE VEGF AND BMP-2 LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THE RELATIONSHIP TO TREATMENT WITH TUMOUR NECROSIS FACTOR ALPHA INHIBITORS

Marian Tošovskýa, Petr Bradnaa, Ctirad Andrýsb, Kateřina Andrýsovác, Eva Čermákovád, Tomáš Soukupa

aCharles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, 2nd Internal Gastroenterological Department, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Czech Republic
dCharles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Institute of Medical Biophysics, Czech Republic

References

1. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arhritis Rheum 2003; 48: 2236–36.
2. Bollow M. Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondylarthropathies: T cell and macrophages predominate in early and active sacroileitis – cellularity correlates with degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59: 135–40. <https://doi.org/10.1136/ard.59.2.135> <PubMed>
3. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324–31. <https://doi.org/10.1002/art.23471>
4. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063–70. <https://doi.org/10.1002/art.23901>
5. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127. <https://doi.org/10.1186/ar2794> <PubMed>
6. Lories RJU, Derese I, deBari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007; 56: 489–497. <https://doi.org/10.1002/art.22372>
7. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. AnnRheum Dis, 2013; 72: 23–28. <https://doi.org/10.1136/annrheumdis-2011-200859>
8. Goldberger C, Dulak J, Duftner C, et al. Vascular endothelial growth factor (VEGF) in ankylosing spondylitis – a pilot study. Wien Med Wochenschr 2002; 152: 223–5. <https://doi.org/10.1046/j.1563-258X.2002.01118.x>
9. Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003; 132: 158–62. <https://doi.org/10.1046/j.1365-2249.2003.02101.x> <PubMed>
10. Poddubnyy D, Conrad K, Haibel H, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondylarthritis. Ann Rheum Dis 2013 Aug 16. doi: 10.1136/annrheumdis -2013-203824. [Epub ahead of print] <https://doi.org/10.1136/annrheumdis-2013-203824>
11. Chen HA, Chen CH, Lin YJ, et al. Association of bone morphogenetic proteins with spinal vision in ankylosing spondylitis. J Rheumatol 2010; 37(10): 2126–32. <https://doi.org/10.3899/jrheum.100200>
12. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8. <https://doi.org/10.1002/art.1780270401>
13. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38: 878–82. <https://doi.org/10.1093/rheumatology/38.9.878>
14. Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127–9. <https://doi.org/10.1136/ard.2004.020503> <PubMed>
15. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64: 1388–98. <https://doi.org/10.1002/art.33465>
16. Pedersen SJ, Hetland ML, Sorensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010; 29: 1301–9. <https://doi.org/10.1007/s10067-010-1528-x>
17. Poddubnyy D, Conrad K, Syrbe U, et al. Elevated serum level of the vascular endothelial growth factor is highly predictive for new syndesmophytes formation in patients with ankylosing spondylitis. Arthritis Rheum 2012; 64 (Suppl): S1054. <https://doi.org/10.1002/art.33465>
18. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67: 511–17. <https://doi.org/10.1136/ard.2007.071605> <PubMed>
19. Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 175–82. <https://doi.org/10.1136/ard.2007.084426> <PubMed>
20. Appel H, Janssen L, Listing J, et al. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumour necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008; 10: R125. <https://doi.org/10.1186/ar2537> <PubMed>
21. Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis 2011; 70: 1375–81. <https://doi.org/10.1136/ard.2010.138883>
22. Patil AS, Sable RB, Kothari RM. Occurrence, biochemical profile of vascular endothelial growth factor (VEGF) isoforms and their functions in endochondral ossification. J Cell Physiol 2012; 227: 1298–308. <https://doi.org/10.1002/jcp.22846>
23. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623–8. <https://doi.org/10.1038/9467>
24. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014 Apr 1; 73(4): 710–5. doi: 10.1136/annrheumdis-2012-202698. Epub 2013 Mar 16. <https://doi.org/10.1136/annrheumdis-2012-202698>
25. Haroon N, Inman RD, Learch TJ, et al. The impact of tumour necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65(10): 2645–54.
26. Wanders A, van der Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52(6): 1756–65. <https://doi.org/10.1002/art.21054>
27. Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012; 71(10): 1593–5. <https://doi.org/10.1136/annrheumdis-2012-201844>
28. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuos NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71(10): 1623–9. <https://doi.org/10.1136/annrheumdis-2012-201370>
29. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71(10): 1616–22. <https://doi.org/10.1136/annrheumdis-2011-201252>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive